SCHEMBL10193263

SCHEMBL10193263

CO/C(N)=N\c1cccc2ncc(NC(=O)c3cnc(C)cn3)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
NPC1 O15118 7/20 0.46
SMN1; SMN2 Q16637 7/20 0.46
RAB9A P51151 6/20 0.46
BACE1 P56817 5/20 0.46
GAA P10253 1/20 0.46
TDP1 Q9NUW8 1/20 0.44
MAPT P10636 4/20 0.43
TP53 P04637 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
LMNA P02545 1/20 0.42
HSD17B10 Q99714 3/20 0.42
KDM4E B2RXH2 3/20 0.42
HPGD P15428 2/20 0.42
TSHR P16473 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HTT P42858 2/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10193028 0.89 BACE1 (0.44) ALDH1A1NPC1RAB9ABACE1HSD17B10
SCHEMBL10194914 0.87 ALDH1A1 (0.43) ALDH1A1NPC1SMN1; SMN2RAB9ABACE1
SCHEMBL10193944 0.87 KDM4E (0.43) ALDH1A1NPC1RAB9ABACE1HSD17B10
SCHEMBL10193220 0.86 SMN1; SMN2 (0.49) ALDH1A1NPC1SMN1; SMN2RAB9ABACE1
SCHEMBL10193848 0.83 BACE1 (0.43) ALDH1A1NPC1RAB9ABACE1HSD17B10
SCHEMBL10192951 0.75 BACE1 (0.48) BACE1AURKA
SCHEMBL10193952 0.75 ALDH1A1 (0.52) ALDH1A1NPC1SMN1; SMN2RAB9ABACE1
SCHEMBL10194199 0.74 ALDH1A1 (0.38) ALDH1A1NPC1SMN1; SMN2RAB9AMAPT
SCHEMBL10193249 0.73 BACE1 (0.43) BACE1
SCHEMBL10193707 0.73 PDE4D (0.42) ALDH1A1NPC1SMN1; SMN2RAB9ABACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015961-A1 ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015961-A1 ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY BACE1, BACE2, APP ALDH1A1 1013/4885NPC1 435/4885SMN1; SMN2 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.